Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a sell rating to a hold rating in a research note released on Monday.

Other equities analysts have also issued reports about the company. Maxim Group increased their price objective on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a buy rating in a report on Tuesday, March 19th. Cantor Fitzgerald reiterated an overweight rating and set a $21.00 price target on shares of Actinium Pharmaceuticals in a research note on Monday, April 1st. Finally, HC Wainwright restated a buy rating and issued a $50.00 price objective on shares of Actinium Pharmaceuticals in a research note on Monday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus target price of $25.72.

Actinium Pharmaceuticals Stock Up 8.2 %

Shares of Actinium Pharmaceuticals stock opened at $7.43 on Monday. The firm has a market cap of $218.44 million, a PE ratio of -4.06 and a beta of 0.01. Actinium Pharmaceuticals has a 1 year low of $4.00 and a 1 year high of $9.86.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its quarterly earnings results on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.21. The company had revenue of $0.08 million for the quarter. Equities analysts expect that Actinium Pharmaceuticals will post -1.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ATNM. Creative Financial Designs Inc. ADV boosted its holdings in Actinium Pharmaceuticals by 19.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 3,175 shares during the period. Sanders Morris Harris LLC bought a new stake in Actinium Pharmaceuticals during the first quarter valued at $78,000. Finally, Brandywine Global Investment Management LLC purchased a new position in Actinium Pharmaceuticals during the third quarter worth about $1,033,000. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.